From: The captopril challenge test for diagnosing primary Aldosteronism in a Chinese population
Ā | Pre-CCT | Post-CCT | PAC suppression percentage (%) | ||||
---|---|---|---|---|---|---|---|
PRA (ng/ml.h) | PAC (ng/dl) | ARR | PRA (ng/ml.h) | PAC (ng/dl) | ARR | ||
NC (nā=ā40) | 1.4 (0.91~4.2) | 13.2Ā Ā±Ā 4.7 | 6.9 (3.9~14.4) | 3.0 (1.6~5.3) * | 12.1Ā Ā±Ā 4.4ā | 3.9 (1.8~7.3) ā | 10.2 (āā2.6~20.8) |
PH (nā=ā163) | 2.3 (1.2~3.6) | 13.6Ā Ā±Ā 3.9 | 6.1 (3.5~10.2) | 3.3 (1.8~5.7) ā | 12.2Ā Ā±Ā 4.1ā | 3.4 (2.2~7.0) ā | 10.6 (āā1.4~21.5) |
IHA (nā=ā28) | 0.23 (0.05~0.36)AB | 15.5Ā Ā±Ā 6.4ab | 60.0 (34.8~169.2)AB | 0.31 (0.20~0.58)ABā | 14.9Ā Ā±Ā 5.6aB | 41.1 (27.9~61.2)AB | 3.4 (ā15.1~17.1) |
APA (nā=ā82) | 0.21 (0.048~0.35)AB | 18.2Ā Ā±Ā 4.9ABC | 80.0 (47.7~263.9)AB | 0.30 (0.080~0.53)ABā | 17.4Ā Ā±Ā 5.0ABcā | 54.7 (35.2~196.9)AB | 3.8 (ā5.3~11.7)b |